Provided by Tiger Fintech (Singapore) Pte. Ltd.

Chemomab Therapeutics Ltd.

1.42
+0.05003.65%
Post-market: 1.40-0.0199-1.40%19:37 EDT
Volume:138.92K
Turnover:194.55K
Market Cap:26.78M
PE:-1.83
High:1.43
Open:1.36
Low:1.35
Close:1.37
Loading ...

Company Profile

Company Name:
Chemomab Therapeutics Ltd.
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
3
Office Location:
Building 7,Kiryat Atidim,Tel Aviv,Israel
Zip Code:
6158002
Fax:
- -
Introduction:
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Directors

Name
Position
Dale Pfost
Director, Chief Executive Officer and Chairman
Adi Mor
Director, Chief Scientific Officer
Alan Moses
Director
Claude Nicaise
Director
Joel Maryles
Director
Neil Cohen
Director
Nissim Darvish
Director

Shareholders

Name
Position
Dale Pfost
Director, Chief Executive Officer and Chairman
Donald Marvin
Chief Financial Officer, Executive Vice President and Chief Operating Officer
Adi Mor
Director, Chief Scientific Officer
Arnon Aharon
Outgoing Chief Medical Officer